Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 3 2Phase 1 2Phase 4 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Sigmoidoscopy × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT00893295 2013-12-18

Increasing Colorectal Cancer Screening in African Americans

National Cancer Institute (NCI)

Phase 3 Unknown
896 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡